“By going digital, biotech pioneers with promising biomolecular platforms are improving drug discovery and development—and changing the pharmaceutical industry.” By Olivier Leclerc and Jeff Smith Article & Artwork © McKinsey & Company
“These are three of over 30 biotech IPOs so far in 2018, which is tracking to be a top quartile year for IPO volume and value since the beginning of the industry. As predicted back in…
Kingfisher Talent, the Boston-based consortium for biotech executive search and leadership development, and d`Anvers & Co, a bespoke relocation and real estate services company, will collaborate to provide a comprehensive offering of settling in services for…
